EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Vitiligo Trial to Initiate in Mid-2026 Edesa Biotech, Inc.

A new study suggest that using CXCL9 and CXCL10-producing dendritic cells alongside immunotherapy can be a promising strategy to overcome treatment resistance and improve clinical outcomes for ...

Preservation of long-term neurocognitive function by hippocampal avoidance whole-brain radiotherapy in patients with brain metastases. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A ...

WEST HILLS, Calif.--(BUSINESS WIRE)-- For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of ...

In this new analysis, results showed that CCL3, CXCL8, CXCL9, and CXCL10 may be indicators of disease severity. Researchers are shedding light on serum indicators that may be associated with disease ...

The IL-6 pathway is involved in atherosclerosis, since its inhibitory targeting reduced atherosclerotic lesions in mouse models. Using variants of the IL6 receptor (IL-6R) as proxies for ...

Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease ...